Of the Type 2 Diabetes affected patient that received the treatment, 89% reported positively.
Fenfuro is an innovative product (protected by 7 international patents) involving separations of active ingredients from the natural plant without affecting chemical properties of the active fractions.
It has been clinically evaluated to prove its safety and efficacy.
Efficacy conclusions
- A significant decrease in HbA1C levels was observed as compared to the respective baseline value.
- FENFURO caused a significant reduction in fasting blood sugar levels.
- FENFURO caused a significant reduction in the postprandial (PP) blood sugar levels as compared to the Placebo group as well as compared to the respective baseline value.
- 83% of the patients reported a decrease in fasting sugar levels in FENFURO treated group as compared to 62% in Placebo treated group.
- 89% of the patients reported a decrease in PP sugar levels in FENFURO treated group as compared to 72% of the patients in the Placebo treated group.
- 8% of the patients reported reduced dosage of anti-diabetic therapy in FENFURO treated group, whereas 18.05% of the patients reported reduced dosage of anti-diabetic therapy in Placebo treated group.
Safety conclusions
- No significant change in serum SGOT, SGPT & ALP activities were observed, indicating FENFURO was safe for liver functioning.
- No significant change in blood urea nitrogen and creatinine levels was observed indicating FENFURO was safe for kidney functioning.
- No significant change in haematological parameters was observed.
- Keeping haematological and biochemical results in view, the investigational product was safe for consumption.
Mechanism of Action of Fenfuro:
It is known that in a healthy human body, each cell membrane normally contains some 20000 active insulin receptors whereas an insulin resistance patient cell membrane has around 5000 active insulin receptors, causing excess free-floating insulin and glucose.
- Fenfuro is the first dual-action insulin sensitizer and exhibits hypocholesterolemic activity.
In the presence of high fiber, Furostanolic saponin cells are more sensitive to insulin.
- An increase in the number of insulin receptor sites occurs which are responsive to insulin to stimulate the cells ability to burn glucose (i.e newer insulin receptors with definite insulin-sensitizing activity due to specific effects on the islets of Langerhans in the Pancreas)
- High fibre Furostanolic saponins delay the rate of gastric emptying and slow carbohydrate absorption & thereby reducing insulin requirements. Thereby brings euglycemic effects.
- Furostanolic saponins also increase peripheral utilization of insulin & thereby brings down the hyperinsulinemia, the root cause of diabetic complications.
- High fibre Furostanolic saponins increase the viscosity of the digesta thereby inhibiting cholesterol absorption from the small intestine and also the inhibition of bile acid re-absorption from the terminal ileum. Thus there is a decrease in VLDL, LDL & Triglycerides level whereas no effects on HDL.
FenfuroTM is one of its kind product, which offers a comprehensive solution for the management of blood glucose. It is a natural plant-based product and thus, has no known side effects, unlike other existing available options for Diabetes.
